Results 191 to 200 of about 86,457 (338)

The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma

Cancer Management and Research, 2009
Ibrahim T Aldoss1, Susan M Blumel2, Philip J Bierman21Department of Internal Medicine, Creighton University Medical Center, Omaha, NE, USA; 2Section of Hematology – Oncology, Department of Internal Medicine, University of Nebraska Medical ...
Ibrahim T Aldoss, Susan M Blumel, Philip J Bierman   +2 more
doaj  

Critical appraisal of MGMT in digestive NET treated with alkylating agents [PDF]

, 2020
Louis de Mestier, Anne Couvelard, Anela Blažević, Olivia Hentic, Wouter W. de Herder, Vinciane Rebours, Valérie Paradis, Philippe Ruszniewski, Leo J. Hofland, Jérôme Cros   +9 more
openalex   +1 more source

Chemical Ionization Mass Spectrometry: Fundamental Principles, Diverse Applications, and the Latest Technological Frontiers

Mass Spectrometry Reviews, EarlyView.
ABSTRACT The review examines the evolution of chemical ionization mass spectrometry (CI‐MS), a technique developed in 1966 by Field and Munson. CI is a soft‐ionization method that produces more intense molecular ions with less fragmentation than electron ionization (EI).
Malvika Dutt, Adriana Arigò, Giorgio Famiglini, Pierangela Palma, Achille Cappiello   +4 more
wiley   +1 more source

Sensitization to Radiation and Alkylating Agents by Inhibitors of Poly(ADP-ribose) Polymerase Is Enhanced in Cells Deficient in DNA Double-Strand Break Repair [PDF]

, 2010
Dana A. Löser, Atsushi Shibata, A. Shibata, Lisa Woodbine, Penny A. Jeggo, Anthony J. Chalmers   +5 more
openalex   +1 more source

Human ALKBH6 Is Required for Maintenance of Genomic Stability and Promoting Cell Survival During Exposure of Alkylating Agents in Pancreatic Cancer. [PDF]

Front Genet, 2021
Zhao S, Devega R, Francois A, Kidane D.
europepmc   +1 more source

Enhancing Selective Brain Cancer Therapy: Integrating Nanomedicine and Molecular Dynamics to Target the Cancerous Lipid Composition

Nano Select, EarlyView.
Improving selectivity within therapeutic design is critical to ensure targeted delivery to brain tumors. Targeting the cellular membrane composition distinctive of the blood–brain barrier and brain cancer cells is explored in this review. Nanomedicine can be utilized for precise tumor recognition, and detailed mechanistic interactions of therapeutics ...
Mahnoor Kadri, Dominique de Jong‐Hoogland, Martin B. Ulmschneider   +2 more
wiley   +1 more source

Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer

, 2018
Javier Cortés, José Manuel Pérez-García, Christelle Lévy, P. Gómez Pardo, Hugues Bourgeois, Simon Spazzapan, Noelia Martínez-Jáñez, Ta‐Chung Chao, Marc Espié, J-MA Nabholtz, Xavier González, V. N. Beliakouski, Juanjo García-Gil, Esther Holgado, Mario Campone   +14 more
openalex   +1 more source

Nigericin‐Triggered Phosphodynamics in Inflammasome Formation and Pyroptosis

PROTEOMICS, EarlyView.
ABSTRACT Innate immune signaling relies heavily on phosphorylation cascades to mount effective immune responses. Although traditional innate immune signaling cascades following TLR4 stimulation have been investigated through a temporally quantitative phosphoproteomic lens, far fewer studies have applied these methods to distinct signaling following the
Vanya Bhushan, Clinton J. Bradfield, Sandhini Saha, Sung Hwan Yoon, Iain D. C. Fraser, Aleksandra Nita‐Lazar   +5 more
wiley   +1 more source

Chemotherapy with Alkylating Agents and Dental Anomalies in Children: A Systematic Review. [PDF]

J Clin Med
Gallenzi P, Malatesta A, Staderini E, Guglielmi F.   +3 more
europepmc   +1 more source

Differential Proteomics of Large Extracellular Vesicles in Ovarian Cancer

PROTEOMICS, EarlyView.
ABSTRACT Diverse extracellular vesicles (EVs) are present in all body fluids; however, knowledge of large EVs (lEVs) remains limited. Molecular EV profiles vary depending on EV size and the physiological circulatory system, even within the same patient. In this study, we aimed to characterize the proteomic profile of IEVs in ovarian cancer patients and
Kazuhiro Suzuki, Yusuke Yamamoto, Masami Kitagawa, Eri Asano‐Inami, Kosuke Yoshida, Hiroaki Kajiyama, Akira Yokoi   +6 more
wiley   +1 more source